Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES SEC filings (Ticker: RTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RetinalGenix Technologies Inc. (RTGN) SEC filings page on Stock Titan is intended to provide investors with access to the company’s regulatory disclosures as they become available. RetinalGenix describes itself in public communications as an ophthalmic research and development company focused on high-resolution retinal imaging, its DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, and therapeutic programs for ocular and systemic diseases, including dry age-related macular degeneration and Alzheimer’s disease/dementia.
While no specific SEC filings are listed in the provided data, investors typically look to documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand a company’s business description, risk factors, R&D priorities, and material events. For a developmental-stage company like RetinalGenix, these filings can be especially relevant for reviewing disclosures related to investigational medical devices, intellectual property around retinal imaging and home monitoring, collaborations in genetics and proteomics, and therapeutic development activities.
On Stock Titan, RTGN filings are supplemented with AI-powered summaries designed to explain the key points of lengthy SEC documents in more accessible language. When forms such as 10-K or 10-Q are available, the platform can highlight sections that discuss the company’s ophthalmic imaging technologies, DNA/RNA/GPS Pharmaco-Genetic Mapping™ initiatives, clinical study plans, and drug repurposing programs. If and when Form 4 insider transaction filings appear, they can help users track reported share transactions by directors and officers.
As RetinalGenix advances its investigational imaging systems, home and remote monitoring patents, and therapeutic research, future SEC filings can provide additional context on how the company characterizes its stage of development, its collaborations with laboratory and life sciences partners, and the risks associated with its precision medicine strategy. Stock Titan’s real-time EDGAR updates and AI summaries aim to make these technical documents easier to review and compare over time.
RetinalGenix Technologies (RTGN) filed its Q3 2025 10‑Q, reporting no revenue and a smaller quarterly net loss of
Liquidity is strained: cash was
For the nine months, net loss improved to
RTGN: A shareholder filed a Form 144 notice to sell up to 77,400 common shares with an aggregate market value of $247,680.00. The filing lists Alpine Securities Corporation as broker and targets an approximate sale date of November 10, 2025 on the OTCQB.
The filing notes 18,604,961 shares outstanding. It also discloses prior acquisitions and recent activity: the securities were acquired via warrant exercise dated 09/01/2018, with payment by check on 03/06/2019. Over the past three months, Bayern Capital LLC reported sales of common shares, including 8,000 for $30,718.67 on 10/24/2025, 10,100 for $36,800.27 on 10/27/2025, and 2,500 for $8,063.95 on 10/31/2025.
FAQ
What is the current stock price of RETINALGENIX TECHNOLOGIES (RTGN)?
What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?
